End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
87,400 KRW | -5.82% |
|
-5.41% | +28.91% |
2023 | ST Pharm Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
2021 | ST Pharm Co.,Ltd. Announces Expansion of Oligonucleotide Facility | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With an expected P/E ratio at 45.37 and 29.94 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+28.91% | 1.22B | - | ||
+55.19% | 815B | C+ | ||
+45.51% | 654B | B | ||
-6.09% | 354B | C+ | ||
+21.92% | 337B | B- | ||
+19.64% | 247B | B+ | ||
+3.60% | 229B | A+ | ||
+14.08% | 219B | B- | ||
+10.86% | 171B | C+ | ||
-2.78% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A237690 Stock
- Ratings ST Pharm Co.,Ltd.